Education
About Us
Working with TipRanks
Follow Us
Vanda Pharmaceuticals Inc. (VNDA)
NASDAQ:VNDA
VNDA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.85 - $6.75
Previous CloseN/A
Volume240.10K
Average Volume (3M)650.19K
Market Cap
$251.34M
Enterprise Value-$82.99M
Total Cash (Recent Filing)$169.95M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.38
Next Earnings
Apr 30, 2025EPS Estimate
-0.57Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.33
Shares Outstanding58,316,044
10 Day Avg. Volume618,690
30 Day Avg. Volume650,194
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.40
Price to Cash Flow (P/CF)-38.30
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.33
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-0.42
Enterprise Value/Ebitda2.55
Forecast
1Y Price Target
$16.50Price Target Upside288.24% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
Vanda News
PremiumCompany Announcements
Vanda Pharmaceuticals’ New Drug Application Accepted by FDA
PremiumCompany Announcements
Vanda Sets 2025 Executive Compensation Plans
---
Bulls Say, Bears Say
Bulls Say
Business DevelopmentVanda announced an exclusive, global license agreement with AnaptysBio for imsidolimab, which has successfully completed two registration-enabling global Phase 3 trials.
Financial PerformanceVanda ended 2024 with roughly $375M in cash, cash equivalents, and marketable securities and no debt, providing ample bandwidth for further business development initiatives.
New Drug ApplicationThe FDA accepted for filing the New Drug Application for tradipitant for the treatment of motion sickness.
Bears Say
Operating ExpensesThe operating expenses shall be affected by the $15M payment to Vanda's licensor for imsidolimab.
Regulatory ApprovalThe FDA has accepted Vanda's request for a hearing on the New Drug Application for tradipitant, which could be a key step towards approval for the treatment of gastroparesis.
Regulatory ChallengesGiven the historical issues that have plagued tradipitant at the FDA, including the denial of the previous NDA for approval of the drug in gastroparesis, no contribution from tradipitant in motion sickness or gastroparesis is included in the valuation assessment.
---
Ownership Overview
6.89% Insiders
17.28% Mutual Funds
0.57% Other Institutional Investors
60.83% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
VNDA FAQ
What was Vanda Pharmaceuticals Inc.’s price range in the past 12 months?
Vanda Pharmaceuticals Inc. lowest stock price was $3.85 and its highest was $6.75 in the past 12 months.
What is Vanda Pharmaceuticals Inc.’s market cap?
Vanda Pharmaceuticals Inc.’s market cap is $251.34M.
When is Vanda Pharmaceuticals Inc.’s upcoming earnings report date?
Vanda Pharmaceuticals Inc.’s upcoming earnings report date is Apr 30, 2025 which is in 4 days.
How were Vanda Pharmaceuticals Inc.’s earnings last quarter?
Vanda Pharmaceuticals Inc. released its earnings results on Feb 13, 2025. The company reported -$0.08 earnings per share for the quarter, beating the consensus estimate of -$0.107 by $0.027.
Is Vanda Pharmaceuticals Inc. overvalued?
According to Wall Street analysts Vanda Pharmaceuticals Inc.’s price is currently Undervalued.
Does Vanda Pharmaceuticals Inc. pay dividends?
Vanda Pharmaceuticals Inc. does not currently pay dividends.
What is Vanda Pharmaceuticals Inc.’s EPS estimate?
Vanda Pharmaceuticals Inc.’s EPS estimate is -0.57.
How many shares outstanding does Vanda Pharmaceuticals Inc. have?
Vanda Pharmaceuticals Inc. has 58,316,044 shares outstanding.
What happened to Vanda Pharmaceuticals Inc.’s price movement after its last earnings report?
Vanda Pharmaceuticals Inc. reported an EPS of -$0.08 in its last earnings report, beating expectations of -$0.107. Following the earnings report the stock price went down -5.957%.
Which hedge fund is a major shareholder of Vanda Pharmaceuticals Inc.?
Currently, no hedge funds are holding shares in VNDA
---
Vanda Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$16.50 (288.24% Upside)
$16.50 (288.24% Upside)
Blogger Sentiment
Bullish
VNDA Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 27.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $296.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 2.9%
Last 30 Days ▲ 2.9%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-5.48%
12-Months-Change
Fundamentals
Return on Equity
-3.49%
Trailing 12-Months
Asset Growth
1.20%
Trailing 12-Months
Company Description
Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under development include HETLIOZ (tasimelteon) for the treatment of jet lag disorder, smith-magenis syndrome, pediatric Non-24, autism spectrum, and delayed sleep phase disorder; Fanapt (iloperidone) for the treatment of bipolar disorder and a long acting injectable formulation program for the treatment of schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist, for the treatment of atopic dermatitis, gastroparesis, and motion sickness. The company's products under development also comprise VTR-297, a small molecule histone deacetylase inhibitor for the treatment of hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist for the treatment of psychiatric disorders; a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors for the treatment of dry eye and ocular inflammation, as well as BPO-27 for the treatment of secretory diarrhea disorders, including cholera; and VHX-896, the active metabolite of iloperidone. It markets its products in the United States, Europe, and Israel. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.
---
VNDA Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mixed outlook, with significant revenue growth from Fanapt and successful integration of Ponvory, countered by a substantial decline in Hetlioz sales due to generic competition and increased net losses. The company's robust pipeline and strategic initiatives suggest potential for future growth, but operational and regulatory challenges raise concerns.Read More>---
VNDA Stock 12 Month Forecast
Average Price Target
$16.50
▲(288.24% Upside)
Technical Analysis
Best Analysts Covering VNDA
1 Year
1 Year Success Rate
1/7 ratings generated profit
1 Year Average Return
-15.34%
reiterated a buy rating 2 months ago
Copying Charles Duncan's trades and holding each position for 1 Year would result in 14.29% of your transactions generating a profit, with an average return of -15.34% per trade.
---